Status:
ACTIVE_NOT_RECRUITING
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
Lead Sponsor:
AstraZeneca
Conditions:
Tumor
Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Eligibility Criteria
Inclusion
- cancer which is refractory to standard therapies
- World Health Organization (WHO) performance status 0 to 2
- evidence of post-menopausal status or negative pregnancy test
Exclusion
- Radiotherapy/chemotherapy within 21 days prior to entry
- brain metastases/spinal cord compression unless stable off steroids/anticonvulsants
- evidence of severe/uncontrolled systemic disease
- participated in an investigational drug study within 30 days
Key Trial Info
Start Date :
March 8 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00463814
Start Date
March 8 2007
End Date
December 31 2025
Last Update
November 13 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aurora, Colorado, United States, 80045
2
Research Site
Nijmegen, Netherlands, 6525 GA
3
Research Site
Utrecht, Netherlands, 3584 CX
4
Research Site
Sutton, United Kingdom, SM2 5PT